Insys Therapeutics Inc (NASDAQ:INSY) has been assigned a consensus rating of “Hold” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $9.50.

A number of brokerages have recently commented on INSY. Zacks Investment Research raised Insys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 22nd. ValuEngine raised Insys Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 15th. Oppenheimer reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Wednesday, May 9th. Finally, Cann reiterated an “average” rating on shares of Insys Therapeutics in a research report on Friday, March 2nd.

In related news, Director Brian Tambi sold 166,504 shares of the business’s stock in a transaction that occurred on Thursday, May 10th. The stock was sold at an average price of $6.41, for a total value of $1,067,290.64. Following the completion of the transaction, the director now directly owns 4,000 shares in the company, valued at approximately $25,640. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 67.90% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of INSY. Stone Ridge Asset Management LLC acquired a new position in shares of Insys Therapeutics in the 4th quarter valued at approximately $137,000. JPMorgan Chase & Co. grew its position in shares of Insys Therapeutics by 303.5% in the 1st quarter. JPMorgan Chase & Co. now owns 25,624 shares of the specialty pharmaceutical company’s stock valued at $155,000 after purchasing an additional 19,273 shares during the period. Virtu Financial LLC grew its position in shares of Insys Therapeutics by 96.8% in the 4th quarter. Virtu Financial LLC now owns 20,061 shares of the specialty pharmaceutical company’s stock valued at $193,000 after purchasing an additional 9,866 shares during the period. Raymond James & Associates grew its position in shares of Insys Therapeutics by 93.5% in the 4th quarter. Raymond James & Associates now owns 31,008 shares of the specialty pharmaceutical company’s stock valued at $298,000 after purchasing an additional 14,982 shares during the period. Finally, Deutsche Bank AG grew its position in shares of Insys Therapeutics by 116.1% in the 4th quarter. Deutsche Bank AG now owns 53,827 shares of the specialty pharmaceutical company’s stock valued at $515,000 after purchasing an additional 28,923 shares during the period. Institutional investors and hedge funds own 17.78% of the company’s stock.

Shares of INSY stock traded down $0.13 on Monday, reaching $7.24. The company had a trading volume of 423,888 shares, compared to its average volume of 996,615. The stock has a market cap of $543.97 million, a PE ratio of -14.78 and a beta of 1.09. Insys Therapeutics has a 12 month low of $4.10 and a 12 month high of $14.00.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The company had revenue of $23.90 million during the quarter, compared to the consensus estimate of $25.82 million. Insys Therapeutics had a negative net margin of 188.01% and a negative return on equity of 43.27%. The business’s revenue was down 33.4% compared to the same quarter last year. During the same period last year, the company earned ($0.09) earnings per share. analysts anticipate that Insys Therapeutics will post -0.91 EPS for the current year.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

Analyst Recommendations for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.